Viking Global Invests in BridgeBio Pharma’s Offshoot GondolaBio

Gunderson Dettmer represented client Viking Global in its investment as part of the $300 million financing of GondolaBio, a newly formed joint venture carved out from BridgeBio Pharma, Inc., a biotech designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers.

News coverage regarding the transaction noted that, “GondolaBio will conduct R&D, manufacturing and commercialization activities for early-stage clinical or preclinical programs across three indications: a rare inherited metabolic disorder known as erythropoietic protoporphyria, a genetic lung condition called alpha-1 antitrypsin deficiency and a rare genetic disease called tuberous sclerosis complex.”

The Gunderson Dettmer team was led by Greg Volkmar and Jeff Stricker and included Aliya Sanders, Jace Clegg, Eugene Kim and Greg Miele.

Companies
Viking Global
GondolaBio
BridgeBio Pharma Inc.